Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Adamany

Gastroenterology Mission Viejo, CA Medical Doctor

NPI 1992780688 CMS profile 90378

27871 Medical Center Rd, Suite 200, Mission Viejo, CA 92691

Open in the dashboard

General payments

$5,203

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Adamany of Mission Viejo, CA is reported in the CMS Open Payments database as having received $5,203 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $591 22
2024 General $797 30
2023 General $231 11
2022 General $1,576 82
2020 General $378 20
2019 General $1,629 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Adamany
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ronald Adamany were reported at $591. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ronald Adamany Gastroenterology median Middle half National median
2019 $1,629 $417 $126–$1,100 $163
2020 $378 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $1,576 $448 $129–$1,270 $149
2023 $231 $533 $150–$1,390 $160
2024 $797 $605 $160–$1,606 $164
2025 $591 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,084 88 payments
  2. Pfizer Inc. $608 21 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $506 27 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $310 25 payments
  5. Allergan Inc. $263 15 payments
  6. Genzyme Corporation $256 10 payments
  7. Celgene Corporation $161 11 payments
  8. Covidien LP $142 1 payment
  9. Daiichi Sankyo Inc. $125 7 payments
  10. Merck Sharp & Dohme Corporation $119 9 payments
  11. Other $628 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,183 246 payments
  2. Consulting Fee $20 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $819 34 payments
  2. XELJANZ $457 15 payments
  3. SKYRIZI Immunology $450 19 payments
  4. XIFAXAN $426 22 payments
  5. VELSIPITY $405 15 payments
  6. HUMIRA $272 14 payments
  7. DUPIXENT $256 10 payments
  8. SKYRIZI Immunology $243 8 payments
  9. LINZESS $241 16 payments
  10. CREON $216 12 payments
  11. Other $2,008 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record